Abstract
Glycerol monostearate was used as a pellet-aid to prepare tiagabine HCl/2-HPβCD inclusion complex pellets (an antiepileptic agent partially included into the 2-HPβCD cavity to improve its stability). The pellitization of tiagabine HCl/2-HPβCD inclusion complex (1:1 stoichiometric composition) using 27.3% of melted GMS (60°C) in its liquid form as wetting agent, 30% of microcrystalline cellulose (pellet-forming agent) and 3% of kollidone-30 (binder) was studied. Pellitization was prepared using extrusion/spheronization method. > b 80% of pellets, size ranging between 800-1000μm, were obtained indicating a significant pellet yield. The disintegration test of the pellets complied with the Eur. Ph. Limit (0.8%). The TGB pellets formed were better sized and spherically shaped than when GMS was used in its liquid form. Pellets obtained using tiagabine HCl/2-HPβCD inclusion complex after addition of GMS with very little water content ( < 5%) have also a spherical shape, retain their integrity in dissolution medium, which suggested that coatings will not burst prematurely due to granule swelling and release their TGB load rapidly 65-85% in 15min in a phosphate buffered dissolution medium.
Keywords: Tiagabine, Cyclodextrins, Glycerol Monostearate, Pellets, Extrusion-Spheronization
Letters in Drug Design & Discovery
Title: Preparation of Tiagabine HCl/2-HPβCD Complex Pellets by Extrusion-Spheronization Using Glycerol Monostearate as Pellet-Aid
Volume: 7 Issue: 1
Author(s): Abdussalam Sughir, Malika Lahiani-Skiba and Mohamed Skiba
Affiliation:
Keywords: Tiagabine, Cyclodextrins, Glycerol Monostearate, Pellets, Extrusion-Spheronization
Abstract: Glycerol monostearate was used as a pellet-aid to prepare tiagabine HCl/2-HPβCD inclusion complex pellets (an antiepileptic agent partially included into the 2-HPβCD cavity to improve its stability). The pellitization of tiagabine HCl/2-HPβCD inclusion complex (1:1 stoichiometric composition) using 27.3% of melted GMS (60°C) in its liquid form as wetting agent, 30% of microcrystalline cellulose (pellet-forming agent) and 3% of kollidone-30 (binder) was studied. Pellitization was prepared using extrusion/spheronization method. > b 80% of pellets, size ranging between 800-1000μm, were obtained indicating a significant pellet yield. The disintegration test of the pellets complied with the Eur. Ph. Limit (0.8%). The TGB pellets formed were better sized and spherically shaped than when GMS was used in its liquid form. Pellets obtained using tiagabine HCl/2-HPβCD inclusion complex after addition of GMS with very little water content ( < 5%) have also a spherical shape, retain their integrity in dissolution medium, which suggested that coatings will not burst prematurely due to granule swelling and release their TGB load rapidly 65-85% in 15min in a phosphate buffered dissolution medium.
Export Options
About this article
Cite this article as:
Sughir Abdussalam, Lahiani-Skiba Malika and Skiba Mohamed, Preparation of Tiagabine HCl/2-HPβCD Complex Pellets by Extrusion-Spheronization Using Glycerol Monostearate as Pellet-Aid, Letters in Drug Design & Discovery 2010; 7 (1) . https://dx.doi.org/10.2174/157018010789869389
DOI https://dx.doi.org/10.2174/157018010789869389 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Interaction of Different Proteins with GABA<sub>A</sub> Receptor and their Modulatory Effect on Inhibitory Neural Transmission Leads to Epilepsy
CNS & Neurological Disorders - Drug Targets A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Pyridoxal 5-Phosphate Enzymes as Targets for Therapeutic Agents
Current Medicinal Chemistry Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Immunogenicity, Immunopathogenicity, and Immunotolerance in One Graph
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Neuropharmacology In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry Effect of Valerian Extract on GABRB3 Gene MRNA Expression and Sedation in BALB/C Mice
Current Bioactive Compounds Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety The Quantitative Structure-Activity Relationships between GABAA Receptor and Ligands based on Binding Interface Characteristic
Current Computer-Aided Drug Design Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Neurological Disorders in Pregnancy
Current Women`s Health Reviews Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews